Oric Pharmaceuticals Inc

ORIC remains in a medium-term bullish regime supported by Stage 2 structure and rising EMAs, but near-term overbought signals, parabola-driven exhaustion risk, and resistance near highs argue for patience. A pullback into the confluence of the 9-day and 20-day EMAs would offer the most structurally favorable entry.

• ↑Moderate Buy consensus, $19.27 price target implies ~74% upside
• ↑$280.4M cash extends runway to H2 2024, supports clinical programs
• ↓Negative earnings yield and weak profitability signal operational inefficiencies